Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $12225.0.

  • 60 Degrees Pharmaceuticals' Depreciation and Depletion rose 18207.2% to $12225.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $33604.0, marking a year-over-year increase of 31221.79%. This contributed to the annual value of $11726.0 for FY2024, which is 4458.94% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Depreciation and Depletion of $12225.0 as of Q3 2025, which was up 18207.2% from $9236.0 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $12225.0 during Q3 2025, with a 5-year trough of $407.0 in Q1 2024.
  • For the 4-year period, 60 Degrees Pharmaceuticals' Depreciation and Depletion averaged around $5839.0, with its median value being $6797.5 (2022).
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Depreciation and Depletion crashed by 9410.23% in 2024 and then soared by 154471.74% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $6901.0 in 2022, then crashed by 72.83% to $1875.0 in 2023, then soared by 190.61% to $5449.0 in 2024, then surged by 124.35% to $12225.0 in 2025.
  • Its last three reported values are $12225.0 in Q3 2025, $9236.0 for Q2 2025, and $6694.0 during Q1 2025.